B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 179 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2014', provides an overview of the B-Cell Non-Hodgkin Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the B-Cell Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the B-Cell Non-Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
B-Cell Non-Hodgkin Lymphoma Overview 11
Therapeutics Development 12
Pipeline Products for B-Cell Non-Hodgkin Lymphoma - Overview 12
Pipeline Products for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis 13
B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 14
B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 17
B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies 21
B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 23
B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 24
Bristol-Myers Squibb Company 24
Boehringer Ingelheim GmbH 25
Amgen Inc. 26
Sanofi 27
Seattle Genetics, Inc. 28
Genentech, Inc. 29
MedImmune, LLC 30
Merck & Co., Inc. 31
Millennium Pharmaceuticals, Inc. 32
Biocon Limited 33
Ono Pharmaceutical Co., Ltd. 34
Sandoz Inc. 35
Celgene Corporation 36
Incyte Corporation 37
Merck KGaA 38
Immunomedics, Inc. 39
Portola Pharmaceuticals, Inc. 40
Pharmacyclics, Inc. 41
Takara Bio Inc. 42
Simcere Pharmaceutical Group 43
Spectrum Pharmaceuticals, Inc. 44
Cornerstone Pharmaceuticals, Inc. 45
LFB S.A. 46
Eagle Pharmaceuticals Inc. 47
Areta International s.r.l. 48
Molecular Templates Inc. 49
Aprogen, Inc. 50
BioMedics Japan Inc. 51
B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 56
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
bendamustine hydrochloride RTD - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
bendamustine hydrochloride - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
rituximab biosimilar - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
alisertib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
coltuximab ravtansine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
pralatrexate - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
vorinostat - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
moxetumomab pasudotox - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
BVX-20 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
DI-Leu16-IL2 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
ublituximab - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
PRT-2070 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
CD19-CAR Gene Therapy - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
MDX-1203 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
SGN-CD19A - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
milatuzumab - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
ibrutinib - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
CPI-613 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
CD19.CAR-CD28Z T Cells - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
urelumab - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
NSC-678515 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Cell Therapy for Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
CC-292 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
EMD-521873 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
rituximab biosimilar - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
BI-836826 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
AMG-319 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
ONO-4059 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
BM-ca - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
INCB-40093 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
GDC-0853 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Cell Therapy for Leukemia - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
INCB-050465 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
bendamustine hydrochloride SI - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
rituximab biosimilar - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Recombinant Idiotypic VK3-20 Vaccine - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
MT-3724 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
rituximab biosimilar - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
rituximab biosimilar - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
PLS-123 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
SH-7133 - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
SH-7129 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
202-b - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
SH-7113 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates 129
B-Cell Non-Hodgkin Lymphoma - Dormant Projects 163
B-Cell Non-Hodgkin Lymphoma - Discontinued Products 164
B-Cell Non-Hodgkin Lymphoma - Product Development Milestones 165
Featured News & Press Releases 165
Jul 08, 2014: Eagle Pharmaceuticals Receives Orphan Drug Designation for Lower Volume, Shorter Infusion Time Bendamustine Hydrochloride Product for Chronic Lymphocytic Leukemia and Indolent B-Cell Non-Hodgkin's Lymphoma 165
Apr 18, 2014: Molecular Templates Presents Preclinical Data on Engineered Toxin Bodies (ETB) at the AACR Annual Meeting 165
Dec 10, 2013: Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies 166
Sep 17, 2013: FDA Approves Teva's TREANDA Injection, a New Liquid Formulation 170
Sep 09, 2013: TG Therapeutics' Ublituximab Receives Orphan Drug Designation for the Treatment of Nodal Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma 171
Jun 02, 2013: Infinity Pharma Reports Presentation Of Updated Phase I Data Of IPI-145 In Chronic Lymphocytic Leukemia At ASCO Annual Meeting 171
May 15, 2013: Janssen Oncology Announces Presentation Of Data On Ibrutinib At 2013 ASCO Annual Meeting 174
Feb 11, 2013: TG Therapeutics Opens Expansion Cohorts In Phase I/II Trial Of TG-1101 In Patients With Rituximab Relapsed Or Refractory B-cell Non-Hodgkin's Lymphoma 175
Feb 06, 2013: Seattle Genetics Initiates Two Phase I Trials Of SGN-CD19A 176
Dec 11, 2012: Celgene Presents Data Evaluating Combination Treatments Including Revlimid Plus Antibody Therapies In Patients With Various Forms Of Non-Hodgkin Lymphoma At ASH 2012 176
Appendix 178
Methodology 178
Coverage 178
Secondary Research 178
Primary Research 178
Expert Panel Validation 178
Contact Us 179
Disclaimer 179

List of Tables
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H2 2014 12
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Late Stage Development, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Development by Companies, H2 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2014 23
B-Cell Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2014 24
B-Cell Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 25
B-Cell Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H2 2014 26
B-Cell Non-Hodgkin Lymphoma - Pipeline by Sanofi, H2 2014 27
B-Cell Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2014 28
B-Cell Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H2 2014 29
B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H2 2014 31
B-Cell Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 32
B-Cell Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 34
B-Cell Non-Hodgkin Lymphoma - Pipeline by Sandoz Inc., H2 2014 35
B-Cell Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H2 2014 36
B-Cell Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H2 2014 37
B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H2 2014 38
B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H2 2014 39
B-Cell Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 40
B-Cell Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2014 41
B-Cell Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc., H2 2014 42
B-Cell Non-Hodgkin Lymphoma - Pipeline by Simcere Pharmaceutical Group, H2 2014 43
B-Cell Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 44
B-Cell Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2014 45
B-Cell Non-Hodgkin Lymphoma - Pipeline by LFB S.A., H2 2014 46
B-Cell Non-Hodgkin Lymphoma - Pipeline by Eagle Pharmaceuticals Inc., H2 2014 47
B-Cell Non-Hodgkin Lymphoma - Pipeline by Areta International s.r.l., H2 2014 48
B-Cell Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H2 2014 49
B-Cell Non-Hodgkin Lymphoma - Pipeline by Aprogen, Inc., H2 2014 50
B-Cell Non-Hodgkin Lymphoma - Pipeline by BioMedics Japan Inc., H2 2014 51
Assessment by Monotherapy Products, H2 2014 52
Number of Products by Stage and Target, H2 2014 55
Number of Products by Stage and Mechanism of Action, H2 2014 58
Number of Products by Stage and Route of Administration, H2 2014 60
Number of Products by Stage and Molecule Type, H2 2014 62
B-Cell Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H2 2014 129
B-Cell Non-Hodgkin Lymphoma - Dormant Projects, H2 2014 163
B-Cell Non-Hodgkin Lymphoma - Discontinued Products, H2 2014 164